Posted by Michael Wonder on 05 May 2023
Dupixent (dupilumab injection) is now approved in Canada for the treatment of adult and adolescent patients (12+) with eosinophilic esophagitis
4 May 2023 - This is the eighth indication for Dupixent in Canada and its first in gastroenterology.
Sanofi Canada is pleased to announce that Health Canada has issued a Notice of Compliance for Dupixent (dupilumab injection) for the treatment of patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis.
